Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report

Cornford, 2017, EAU- ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur. Urol., 71, 630, 10.1016/j.eururo.2016.08.002 Dalesio, 2000, Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2 Gillessen, 2020, Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference, Eur. Urol., 77, 508, 10.1016/j.eururo.2020.01.012 Halabi, 2016, Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer, J. Clin. Oncol., 34, 1652, 10.1200/JCO.2015.65.7270 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Kosaka, 2019, Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: A case report, BMC Cancer, 19, 10, 10.1186/s12885-019-5782-2 Kratochwil, 2016, 225Ac-PSMA-617 for PSMA-targeted a-radiation therapy of metastatic castration-resistant prostate cancer, J. Nucl. Med., 57, 1941, 10.2967/jnumed.116.178673 Kratochwil, 2019, Radionuclide therapy of metastatic prostate cancer, Semin. Nucl. Med., 49, 313, 10.1053/j.semnuclmed.2019.02.003 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N. Engl. J. Med., 369, 213, 10.1056/NEJMoa1213755 Prostate, G., The Global Cancer Observatory 2018. World Heal Organ. 2019;876:1,2. Rebbeck, 2017, Prostate cancer genetics: variation by race, ethnicity, and geography, Semin. Radiat. Oncol., 27, 3, 10.1016/j.semradonc.2016.08.002 Sathekge, 2019, 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study, Eur. J. Nucl. Med. Mol. Imaging, 46, 129, 10.1007/s00259-018-4167-0 Sweat, 1998, Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases, Urology, 52, 637, 10.1016/S0090-4295(98)00278-7 Tucci, 2016, Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis, Eur. Urol., 69, 563, 10.1016/j.eururo.2015.09.013